{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89","upperLimit":"99","value":"97.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Induction ORR was defined as the percentage of participants who achieved partial response or better based on the International Myeloma Working Group Response (IMWG) criteria during induction therapy either 4 cycles or 8 cycles of combination therapy. Response on ASCT is not included.","dispersionType":"90% Confidence Interval","groups":[{"description":"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m\\^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m\\^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.\n\nMaintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m\\^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy.","id":"OG000","title":"Lenalidomide, Subcutaneous Bortezomib, Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Evaluable for disease response analysis having started therapy and assessed for disease post-baseline.","reportingStatus":"POSTED","timeFrame":"Participants were followed up to 24 weeks.","title":"Induction Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}